Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4464900
Max Phase: Preclinical
Molecular Formula: C72H96N14O18S2
Molecular Weight: 1509.77
Molecule Type: Unknown
Associated Items:
ID: ALA4464900
Max Phase: Preclinical
Molecular Formula: C72H96N14O18S2
Molecular Weight: 1509.77
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CSSC[C@H](NC1=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N2
Standard InChI: InChI=1S/C72H96N14O18S2/c1-6-39(3)58-69(101)81-52-38-106-105-37-51(80-62(94)46(31-42-17-10-8-11-18-42)75-56(89)35-73-61(93)48(34-57(90)91)77-67(99)53-21-14-28-84(53)70(102)49(78-66(52)98)33-43-19-12-9-13-20-43)65(97)74-41(5)60(92)76-47(32-44-24-26-45(88)27-25-44)63(95)79-50(36-87)64(96)83-59(40(4)7-2)72(104)86-30-16-23-55(86)71(103)85-29-15-22-54(85)68(100)82-58/h8-13,17-20,24-27,39-41,46-55,58-59,87-88H,6-7,14-16,21-23,28-38H2,1-5H3,(H,73,93)(H,74,97)(H,75,89)(H,76,92)(H,77,99)(H,78,98)(H,79,95)(H,80,94)(H,81,101)(H,82,100)(H,83,96)(H,90,91)/t39-,40-,41-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,58-,59-/m0/s1
Standard InChI Key: JHNKACLONXTFOI-DUPHBKPXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1509.77 | Molecular Weight (Monoisotopic): 1508.6468 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Li CY, Yap K, Swedberg JE, Craik DJ, de Veer SJ.. (2020) Binding Loop Substitutions in the Cyclic Peptide SFTI-1 Generate Potent and Selective Chymase Inhibitors., 63 (2): [PMID:31855419] [10.1021/acs.jmedchem.9b01811] |
Source(1):